State treasurers urge Gilead to lower the price of remdesivir
In a letter to the drug maker, the state treasurers warn that prices “disconnected from market forces will ultimately backfire.”
Related Articles
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South Africa, and more
Cigna plans to make copies of AbbVie’s Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
Vertex offers limited access to a cystic fibrosis drug in South Africa — and may undercut a court case
“This is not a solution for all South African patients” and is “likely to widen the disparity between rich and poor,” advocates complained.
Colombia issues a compulsory license for an HIV medicine and ‘plants a flag for global health equity’
“Colombia is planting a flag for global health equity,” said Peter Maybarduk, who heads the access to medicines campaign at Public Citizen.
Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
Colombia issues a compulsory license for an HIV medicine and ‘plants a flag for global health equity’
“Colombia is planting a flag for global health equity,” said Peter Maybarduk, who heads the access to medicines campaign at Public Citizen.
Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds
The authors of a new study argue the heralded arrival of biosimilars failed to fully deliver on their promise.
Colombia issues a compulsory license for an HIV medicine and ‘plants a flag for global health equity’
“Colombia is planting a flag for global health equity,” said Peter Maybarduk, who heads the access to medicines campaign at Public Citizen.
Pharmalittle: We’re reading about GLP-1 spending, biosimilar patient costs, and more
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they’re set to cost the U.S. health care system and the federal government…
Pharmalittle: We’re reading about Lilly buying a plant, a Pfizer antibiotic, and more
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.